Can cognitive technology assist with melanoma identification?
29 June 2016
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology – sometimes called ‘artificial intelligence’.
Melanoma Institute Australia operates the world’s largest melanoma research and treatment facility, and controls the largest melanoma research database in the world. “Research that enables the earlier detection of melanoma is likely to save more lives in the future,” says Professor Graham Mann, Research Director at Melanoma Institute Australia. “The five-year survival rate for melanoma is only 64 percent once the disease reaches the lymph nodes. However this rises to 95 percent if detected before then. Diagnosing melanoma with the naked eye is only about 60 percent accurate, but dermoscopy can lift that to over 80 percent. Research using automated analysis of images could provide the next gain in accuracy, especially where dermoscopy is hard to access.”
Using advanced visual analytics IBM Research will conduct retrospective analysis on de-identified data, which will include access to more than one million images as well as text based clinical notes in an effort to improve the accuracy of its machine learning algorithms. IBM’s cognitive technology would aim to learn to understand skin cancers such as melanoma, basal cell carcinoma and squamous cell carcinoma using lower resolution clinical images, with a goal of similar accuracy to what can be achieved with dermoscopy images.
Dr. Joanna Batstone, Vice President and Lab Director, IBM Research – Australia said, “Cognitive computing has the ability to process vast amounts of complex data including images and text very quickly, something that isn’t possible by current manual methods. Another major benefit of the self-learning technology is that it improves as more and more data is fed into it. This initiative could inform future research and, potentially, the development of offerings that could have enormous implications for both the Australian public and the health system.”
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.
Thank you to everyone involved in making Melanoma March 2016 a huge success
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.